Skip to main content

Table 3 Estimated mean difference in 5-year change from baseline on composite Z score for the three intervention groups compared to the placebo group

From: Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial

Groups

Estimated mean change from baseline (95% CI)

Estimated mean between-group difference in change from baseline (95% CI)

Unadjusted

Adjusteda

vs. placebo

Raw P

Hochberg P

vs. placebo

Raw P

Hochberg P

5-year ITT MAPT-PLUS analysis (n = 483)

Positive plasma Aβ42/40

  Multidomain plus omega 3

-0.2023 (-0.4824; 0.0778)

0.2575 (-0.1004; 0.6154)

0.1579

0.4737

0.2501 (-0.1071; 0.6073)

0.1691

0.5074

  Omega 3 alone

-0.4255 (-0.6705; -0.1804)

0.0343 (-0.2969; 0.3656)

0.8385

0.8385

-0.0288 (-0.3665; 0.3089)

0.8666

0.8666

  Multidomain plus placebo

-0.5209 (-0.7967; -0.2451)

-0.0611 (-0.4157; 0.2935)

0.7348

0.8385

-0.1582 (-0.5153; 0.1988)

0.3838

0.7676

  Placebo

-0.4598 (-0.6827; -0.2369)

-

-

-

-

-

-

Negative plasma Aβ42/40

  Multidomain plus omega 3

-0.2870 (-0.4388; -0.1351)

-0.0358 (-0.2674; 0.1959)

0.7614

0.7614

-0.0237 (-0.2569; 0.2095)

0.8415

0.8415

  Omega 3 alone

-0.1524 (-0.3287; 0.0239)

0.0988 (-0.1495; 0.3471)

0.4339

0.7614

0.1008 (-0.1489; 0.3506)

0.4271

0.8415

  Multidomain plus placebo

-0.3384 (-0.5079; -0.1690)

-0.0872 (-0.3307; 0.1563)

0.4812

0.7614

-0.1107 (-0.3563; 0.1348)

0.3753

0.8415

  Placebo

-0.2512 (-0.4261; -0.0763)

-

-

-

-

-

-

5-year per-protocol MAPT-PLUS analysis (n = 457)

Positive plasma Aβ42/40

  Multidomain plus omega 3

-0.1315 (-0.4197; 0.1567)

0.3233 (-0.0453; 0.6919)

0.0853

0.2560

0.3202 (-0.0475; 0.6880)

0.0876

0.2628

  Omega 3 alone

-0.4254 (-0.6737; -0.1771)

0.0293 (-0.3090; 0.3677)

0.8645

0.8645

-0.0423 (-0.3874; 0.3028)

0.8095

0.8095

  Multidomain plus placebo

-0.5349 (-0.8177; -0.2522)

-0.0802 (-0.4445; 0.2842)

0.6652

0.8645

-0.1807 (-0.5482; 0.1868)

0.3340

0.6679

  Placebo

-0.4548 (-0.6846; -0.2250)

-

-

-

-

-

-

Negative plasma Aβ42/40

  Multidomain plus omega 3

-0.2920 (-0.4524; -0.1315)

-0.0378 (-0.2773; 0.2016)

0.7559

0.7559

-0.0277 (-0.2686; 0.2132)

0.8209

0.8209

  Omega 3 alone

-0.1613 (-0.3418; 0.0192)

0.0929 (-0.1605; 0.3462)

0.4710

0.7559

0.0825 (-0.1719; 0.3370)

0.5234

0.8209

  Multidomain plus placebo

-0.3388 (-0.5183; -0.1593)

-0.0847 (-0.3373; 0.1679)

0.5098

0.7559

-0.1017 (-0.3570; 0.1536)

0.4334

0.8209

  Placebo

-0.2541 (-0.4319; -0.0764)

-

-

-

-

-

-

  1. ITT Intention-to-treat, MAPT Multidomain Alzheimer Prevention Trial
  2. aAnalysis adjusted for age, sex, level of education, APOE ε4 genotype, and clinical dementia rating global score